All In Biotech

Drug Trial Radar · NCT06634849

An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).

A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256.

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 4, 2024

Primary completion

Apr 30, 2027

Study completion Oct 30, 2027

Sponsor

Lead sponsor
Pathios Therapeutics Pty LtdIndustry
Sponsor type
Industry
First posted
Oct 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open label, dose escalation module will evaluate the safety, tolerability, PK, PD, and preliminary efficacy of PTT-4256 in participants with solid tumours using a combination of accelerated dose titration (ADT) and Bayesian Optimal Interval (BOIN) design.

Conditions

  • Advanced Solid Tumor

Interventions

  • PTT-4256Drug

    Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohorts A1-A5 will receive 10mg, 20mg, 40mg, 80mg \& 160mg. Following review by SRC, Cohort A6 participants will receive 300mg PTT-4256 daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment emergent adverse events (TEAEs), Adverse events and Serious Adverse events as assessed by CTCAE V5.0Time frame: First dose IMP to 21 to 28 days after last IMP dose.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Blacktown Hospital

    Blacktown, New South Wales, Australia · Recruiting

  • Scientia Clinical Research

    Randwick, New South Wales, Australia · Recruiting

  • Southern Oncology Clinical Research Unit (SOCRU)

    Adelaide, South Australia, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.